基于网络药理学对降脂护肝胶囊干预脂肪肝的机制研究

目的 应用网络药理学方法，探讨降脂护肝胶囊（JZHG）治疗脂肪肝（FL）的可能机制，为其临床用药提供理论指导。方法 利用TCMSP与TCMID检索JZHG的活性成分和靶点，通过GeneCard与OMIM数据库检索FL的相关靶点，并采用交集法筛选出二者的共同靶点，运用Cytoscape构建“活性成分-靶点”网络，利用STRING软件构建PPI网络。通过 Bioconductor 数据库以及R软件进行GO和KEGG富集分析。结果 根据口服生物利用度和类药性筛选出46种活性成分，从GeneCard与OMIM数据库中筛选靶点7406个。成分靶点与疾病靶点取交集，获得118个共同靶点。这些靶点主要参与氧化应激、细胞凋亡、炎症反应、激素抵抗等生物学过程。其作用机制与PI3K-Akt信号通路，人巨细胞病毒感染和癌症中的微小RNA等信号通路有关。结论 JZHG中的活性化合物干预脂肪肝的机制可能是通过抗氧化应激和抗炎等作用改善脂代谢，降低肝脏脂肪堆积实现的。

Mechanism of Jiangzhihugan capsule in treatment of fatty liver based on network pharmacology

Objective To explore the potential mechanism of Jiangzhihugan capsule (JZHG) for fatty liver (FL), and to provide a theoretical guideline for the clinical application of JZHG.Methods TCMSP and TCMID databases were used to search for the active components and targets of JZHG. GeneCards and OMIM database were used to search the FL related targets. The intersection method was used to identify the common targets of JZHG and FL. Cytoscape software was applied for the construction of active compounds-targets network map. Protein-protein interaction network was constructed by STRING software. Gene ontology functional enrichment analysis and KEGG pathway enrichment analysis were conducted with Bioconductor database and R software.Results 46 potential active components were screened out from JZHG. 7406 targets were retrieved through GeneCard and OMIM database. 118 genes were obtained from the intersection of component-target and disease-target. These genes were mainly involved with the response to oxidative stress, apoptosis, inflammatory response, hormone resistance and other biological processes. The mechanism was related to PI3K-Akt signaling pathway, human cytomegalovirus infection, microRNAs in cancer, etc.Conclusion The mechanism of active ingredients for FL in JZHG may be due to improving lipid metabolism and reducing liver fat accumulation through anti-oxidative stress and anti-inflammatory effects.